ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

0RAM Vistin Pharma Asa

11.25
0.00 (0.00%)
27 Jun 2024 - Closed
Delayed by 15 minutes
Share Name Share Symbol Market Type Share ISIN Share Description
Vistin Pharma Asa LSE:0RAM London Ordinary Share NO0010734122 VISTIN PHARMA ORD SHS
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 11.25 0.00 01:00:00
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
Pharmaceutical Preparations 438.33M 45.64M 1.0293 10.93 498.88M

Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

04/03/2024 7:15am

UK Regulatory


Vistin Pharma Asa (LSE:0RAM)
Historical Stock Chart


From Dec 2023 to Jun 2024

Click Here for more Vistin Pharma Asa Charts.
Vistin Pharma ASA (VISTN) acquires minority share in CF Pharma (Hungary)

Oslo, Norway, 4 March 2024

Vistin Pharma has aquired a 15% share in CF Pharma Kft. CF Pharma is an API CDMO located in Budapest, Hungary with a broad customer base of recognized international pharmaceutical companies. CF Pharma has a proven track record in developing and commercializing Active Pharmaceutical Ingredients (APIs). The group/company currently has five commercial APIs on the market, with another eight APIs under development.

The transaction price consists of a base price and an earn-out- element, with an agreed cap of MEUR 1.6.

“We have had positive discussions with CF Pharma management and the majority shareholders for some time, to evaluate different partnership models. I am very pleased to announce that Vistin Pharma now has acquired a minority stake in CF Pharma. We see this as a first agreed step in a potential closer partnership in the future, which can broaden our product portfolio and form an important basis for future growth. The cooperation with CF Pharma is a first move in order for Vistin Pharma to execute on the strategy to become a multi-product European API Contract Development and Manufacturing Organization (API CDMO)”, says Magnus Tolleshaug, CEO in Vistin Pharma."


For further information, please contact:

Magnus Tolleshaug
CEO
+47 48 40 52 46
magnus.tolleshaug@vistin.com

Alexander Karlsen
CFO
+47 97 05 36 21
alexander.karlsen@vistin.com

 

This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.


1 Year Vistin Pharma Asa Chart

1 Year Vistin Pharma Asa Chart

1 Month Vistin Pharma Asa Chart

1 Month Vistin Pharma Asa Chart